Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2023 February Clinical trials KRd regimen after stem cell transplantation delays disease progression in multiple myeloma Read more
2023 February Covid-19 Chemotherapy should be delayed in AML patients diagnosed with COVID-19 Read more
2023 February Clinical trials Enasitenib outperforms conventional care in pretreated older IDH2-mutant R/R AML patients Read more
2023 February Pharma News FDA approves pirtobrutinib for the treatment of advanced relapsed/refractory mantle cell lymph... Read more
2023 February CongressUpdate Haematologic diseases and potential future treatments: Award winners at the 2022 annual BSTH m... Read more
Top
